List view / Grid view
...phase III BRAF V600-mutant metastatic melanoma study stopped early.
18 July 2014 | By GlaxoSmithKline
...phase III BRAF V600-mutant metastatic melanoma study stopped early.
GlaxoSmithKline plc announced the start of a Phase III study,…
26 June 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced the start of a Phase III study, SUPPORT (TRC112121), to evaluate the platelet supportive care effects of eltrombopag (Promacta™/Revolade™)...
GlaxoSmithKline plc announced that the Phase III study of two…
2 June 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the Phase III study of two anti-HER2 agents, lapatinib (Tykerb™/Tyverb™) and trastuzumab, did not meet the primary endpoint of improved disease free survival...
GlaxoSmithKline plc announced the formation of the Oncology Clinical and…
5 December 2013 | By GlaxoSmithKline
GlaxoSmithKline plc announced the formation of the Oncology Clinical and Translational Consortium...
“This EU filing, the third for pazopanib in less than…
6 August 2013 | By GlaxoSmithKline
“This EU filing, the third for pazopanib in less than five years, confirms GSK’s commitment to deliver our oncology pipeline..."
“A sustained virologic response is the goal for treatment of…
26 July 2013 | By GlaxoSmithKline
“A sustained virologic response is the goal for treatment of hepatitis C infection..."
The EMA's CHMP is recommending marketing authorisation for two cancer…
28 June 2013 | By GlaxoSmithKline
The EMA's CHMP is recommending marketing authorisation for two cancer drugs...
GSK announced that its Phase III clinical trial of VOTRIENT...
1 June 2013 | By GlaxoSmithKline
GSK announced that its Phase III clinical trial of VOTRIENT...
GSK announced submission of a Marketing Authorisation Application...
7 February 2013 | By GlaxoSmithKline
GSK announced submission of a Marketing Authorisation Application...
GSK announced the start of COMBI-AD...
1 February 2013 | By GlaxoSmithKline
GSK announced the start of COMBI-AD...
GlaxoSmithKline announced regulatory submissions in the European Union and US...
3 August 2012 | By GlaxoSmithKline
GlaxoSmithKline announced regulatory submissions in the European Union and US...
GlaxoSmithKline has withdrawn a supplemental New Drug Application to the…
12 July 2012 | By GlaxoSmithKline
GlaxoSmithKline has withdrawn a supplemental New Drug Application to the US FDA for Tykerb...
Phase III studies of single agent therapy in metastatic melanoma…
4 June 2012 | By
Phase III studies of single agent therapy in metastatic melanoma with BRAF V600 mutations meet primary endpoints...
GlaxoSmithKline plc. announced the start of a Phase III programme...
29 May 2012 | By GlaxoSmithKline
GlaxoSmithKline plc. announced the start of a Phase III programme...
“Treatment options for patients with advanced soft tissue sarcoma are…
20 March 2012 | By GlaxoSmithKline
“Treatment options for patients with advanced soft tissue sarcoma are limited..."
